drugset / Trial / NCT06138834

EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)

NCT06138834

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.

Timeline

Start
2023-11
Primary completion
2024-11
Completion
2025-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 25 mg
Subject Cilostazol Small molecule 100 mg
Subject Y-6 Unknown Other